Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Allena Pharmaceuticals, Inc. (ALNA) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/10/2021 8-K Quarterly results
Docs: "Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress  ALLN-346, a first-in-class, non-absorbed, orally administered enzyme in development for the treatment of hyperuricemia and gout in the setting of advanced chronic kidney disease, receives Fast Track Designation from FDA  Two Phase 2a trials for ALLN-346 enrolling patients with gout and chronic kidney disease; initial data expected in Q1 2022  First interim analysis for URIROX-2 Phase 3 trial of reloxaliase for the treatment of enteric hyperoxaluria planned for Q1 2022  Registered direct offering completed in Q3 raising gross proceeds of $28.0 million"
05/11/2021 8-K Quarterly results
Docs: "Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update"
11/09/2020 8-K Quarterly results
Docs: "Allena Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update"
08/05/2020 8-K Quarterly results
05/13/2020 8-K Quarterly results
Docs: "Cash Position: As of March 31, 2020, cash and cash equivalents were $20.5 million, as compared to $30.0 million as of December 31, 2019. This decrease was primarily due to cash used in operating activities, payment of the Company’s annual bonus and restructuring charges associated with a reduction of workforce completed in December 2019, and payments of principal and interest made on the Company’s credit facility. • R&D Expenses: R&D expenses were $4.6 million for the first quarter of 2020 as compared to $9.1 million for the first quarter of 2019. The decrease was primarily due to a reduction of costs incurred for the reloxaliase program, including costs for the URIROX-1, URIROX-2 , and Study 206 trials. Both the URIROX-1 and Study 206 trials were completed in the fourth quarter of ..."
03/16/2020 8-K Quarterly results
Docs: "Cash Position: As of December 31, 2019, cash and cash equivalents were $30.0 million, as compared to $61.6 million as of December 31, 2018. This decrease was primarily due to cash used in operating activities, partially offset by $12.0 million of net proceeds from the issuance of common stock during 2019. • R&D Expenses: R&D expenses were $8.7 million for the fourth quarter of 2019 and $37.2 million for the year ended December 31, 2019, as compared to $7.3 million for the fourth quarter of 2018 and $26.4 million for the year ended December 31, 2018. This increase was primarily due to costs incurred for the URIROX-2 trial, which was initiated in the fourth quarter of 2018, an increase in formulation and development costs incurred advancing ALLN-346 to IND and an increase in employee-..."
11/13/2019 8-K Quarterly results
08/07/2019 8-K Quarterly results
Docs: "Cash Position: As of June 30, 2019, cash and cash equivalents were $48.5 million, as compared to $61.6 million as of December 31, 2018. This decrease was primary due to cash used in operating activities, partially offset by aggregate gross proceeds of approximately $10 million from the Company’s registered direct offering of common stock, which closed in June 2019. • R&D Expenses: R&D expenses were $8.6 million for the second quarter of 2019, as compared to $5.9 million for the second quarter of 2018. The increase was primarily due to costs incurred for the URIROX-2 trial, which was initiated during the fourth quarter of 2018, and an increase of formulation and development costs incurred advancing ALLN-346. • G&A Expenses: G&A expenses were $2.7 million for the second quarter..."
05/08/2019 8-K Quarterly results
Docs: "Allena Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update"
03/07/2019 8-K Quarterly results
11/07/2018 8-K Quarterly results
Docs: "Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update"
08/07/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Allena Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update"
05/08/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Allena Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update"
03/27/2018 8-K Quarterly results
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registran...",
"Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update"
12/14/2017 8-K Quarterly results
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registran...",
"Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy